Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

Adjuvant gefitinib provides no overall survival (OS) benefit over standard chemotherapy for EGFR-mutant, resected, stage II-IIIA non–small cell lung cancer (NSCLC), according to final results ...

The targeted therapy gefitinib should be considered a first-line therapy for nonsmoking Asian patients with adenocarcinoma of the lung, one of the most common types of lung cancer, suggests a ...

Gefitinib, as compared with carboplatin–paclitaxel, was associated with a lower rate of grade 3 or 4 adverse events, as defined according to the Common Terminology Criteria for Adverse Events ...

Gefitinib was kindly provided by AstraZeneca (Rueil-Malmaison, France) as a micronised powder. Aliquots were stored as a 10 mM stock solution in pure dimethyl sulphoxide (DMSO), and dilutions ...

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point. The phase 3 trial found that adding chemotherapy to gefitinib improved ...

However, their otherwise comprehensive review has failed to mention the adverse cardiovascular effects of erlotinib and gefitinib. As cardiologists in a hospital for patients with cancer ...

Details concerning the Gefitinib medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

The Appraisal Committee considered evidence submitted by the manufacturer of gefitinib and a review of this submission by the Evidence Review Group (ERG). The manufacturer's decision problem compared ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of gefitinib for locally advanced or metastatic NSCLC, having considered evidence on the nature of locally ...